At least your $SLNO report was based on actual in-human data.
What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show!
BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor.
I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites.
You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out.
Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"...
BTW, your own malignancy event table shows a malignancy rate BELOW background rates....???
You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you?
So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!"
BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk...
You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity...
Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
$ABVX completely round tripping this back up from this dip by close today is gonna tell you all you needed to know about the (lack of) validity of this report.
Staying tuned 🍿
$ABVX Scorpion report is just silly. The entire argument is based on preclinical wet lab "research". The report makes all these outlandish claims about what the drug "might" do based on their lab work, then ignores that all of those potential "problems" have been completely debunked by ACTUAL REAL WORLD DATA.
The drug is post phase 3 already people. We already know the safety profile. The theories they published in this "short report" are *literally* the exact bear theses people were talking about 6 years ago for $ABVX. Wet lab based *theories* about the molecule itself. The difference today is that.....we literally have all the real world in human data now, AND NONE OF THOSE SCARY THEORIES TURNED OUT TO BE TRUE.
I'm with @Biohazard3737 - I increased by exposure to $ABVX this morning.
I suspect that this report coming out also explains the recent weakness in the stock. Scorpion has supposedly been working on this for 11 months. Word going around about this report is probably what caused that short report rumor and flash crash back in June too. And since then, we got EVEN MORE data proving the safety concerns are debunked. I have been baffled by even seeing the stock languishing in the $80s recently. Now I understand why that's been the case.
I've already talked to a lot of smart people on this. The near universal response is laughter/mockery. This is simply not serious work.
Congrats to Scorpion though for finding a weak stock to attack and then cover your short on a Friday Opex. $ABVX will be fine.
This might be the most retarded gibberish I have ever read in my life.
The actual thesis here is simple: A) Stock w/ heavy retail presence that are likely to get spooked by this B) Market with limited institutional participation beyond specialists whose long model is generally buy and hold C) Specialists likely stretched thin via blown-up shorts, and specialist books in general being down significantly on the heels of $MRNA, $SLS, etc and terrible performance of a lot of quality biotechs as of late. D) Specialists highly concentrated in $ABVX E) Terrible market conditions
Drop a short report and of course the stock is going to get blown up.
Incredibly transparent. Wild to see.
$ABVX Scorpion called Abivax a fraud. To believe that requires the reader to completely dismiss the very large clinical dataset and/or believe this is the greatest conspiracy in the history of medicine by an order of magnitude. Show the falsified records. Show the cancer excess at the dose you’re attacking. Explain why blinded readers saw healthier colons on both scopes and biopsies. The evidence Scorpion made public falls well short of its headline, and they themselves tell you that they've already covered their short position by the time you read through the report. https://t.co/1v2442xxXd
Start with 50 mg dose.
In June, we estimated 0.59 cancers per 100 patient-years at 50 mg, excluding non-melanoma skin cancer. We kept the doses separate because 50 mg was the dose under scrutiny. Abivax’s July deck put the updated number at 0.64 across 944 patient-years at 50 mg, within its historical ulcerative colitis range of 0.30–0.70. Non-melanoma skin cancer also came in at 0.64, below the company’s 0.70–1.40 benchmark. Those are the 50 mg numbers. https://t.co/6OIuirQaVy · https://t.co/xepAr25GAg
Yes, the narrower Phase 3 maintenance analysis came in higher. Four cases over 438 patient-years gave you 0.91. The added Part 2 data had two cases over 288 patient-years, or 0.69. One patient had a platelet count over 900,000 at baseline and was later diagnosed with a blood-cell cancer. The other was diagnosed with prostate cancer after roughly three months on the drug. Investigators assessed both as unrelated. Then you get to the full 50 mg dataset and the rate is 0.64. If your case depends on the smaller slice, explain why the rest of the exposure should count for less rather than ignoring it because it's inconvenient to your short report credibility. https://t.co/zNf3b6Epa9
Scorpion’s UVA experiment is a lab measurement of light absorption. The public trial protocol already disclosed animal phototoxicity for obefazimod’s main breakdown product and required sun precautions and skin monitoring. The observed 50 mg skin cancer rate across Phase 2 and 3 still came in below the historical benchmark. That comparison leaves room for a rare or delayed risk, but again no evidence. It makes the sweeping cancer claim a lot harder to sell AND physicians are already screening for skin cancer risk due to OTHER STANDARD OF CARE DRUGS THAT CAUSE CANCER IN THESE PATIENTS AND CAN CONFOUND THE SKIN CANCER FINDINGS IN EXPERIMENTAL DRUG TRIALS. https://t.co/ExeBddasfX · https://t.co/f2aPtFmTKQ · https://t.co/H48oz618HP
Now explain the biopsies.
Two blinded Phase 3 trials randomized 1,275 patients. At 50 mg, eight-week remission was 21.7% vs 2.5% on placebo in one trial and 19.8% vs 6.3% in the other. The 25 mg dose missed the main endpoint in the second trial. The 50 mg dose hit it in both. https://t.co/kIH07dLP5U
Then 580 patients who had responded to obefazimod were randomized again. After 44 more weeks, 51% were in remission on either dose versus 10% after switching to placebo. A normal-looking colon on scope? 42% at 25 mg, 48% at 50 mg, 10% on placebo. Improvement confirmed by both scope and biopsy? 50%, 57%, 10%. If widespread gut-cell damage is your explanation for how this drug works, explain why the tissue looked healthier under the microscope. https://t.co/fAifEz9rzj
And the evidence goes back further. All three doses improved the main disease-activity score in the 254-patient Phase 2b trial. In the open-label follow-up, 114 of 217 were in remission at two years, with missing results counted as failures. In a separate, selected group that stepped down to 25 mg, 88 of 130 were in remission three years later. That’s a substantial record of follow-up on top of the three blinded Phase 3 trials. https://t.co/BQhLL9oKBT · https://t.co/eHSpdoGwCY · https://t.co/ItNwwpID4a
“Foreign trials” is doing a lot of work here.
The Phase 3 trials enrolled across 36 countries. Eastern Europe accounted for 38% of enrollment. In Western Europe, 50 mg remission was 19.0% vs 5.6% on placebo. In a smaller exploratory North American group, it was 8 of 62 vs 0 of 36, with scopes also favoring treatment. The protocol called for independent central readers who were blinded to treatment and visit order. If Scorpion has evidence of misconduct, show the sites, the records and what happens to the results when those sites are removed. https://t.co/o41Gr041SS · https://t.co/1Xw3hZbeFj · https://t.co/gk312wXG9J · https://t.co/Y5AbHVJ4kq
The “150-fold” experiment used zero cells. ZERO CELLS. Why are we relying on experiments that don't even include living cells when we have thousands of patient years worth of safety data?
Scorpion measured about one-fifth of the nominal drug concentration in a cell-free reconstruction, then applied that result to cell data from 2015 to get the 150-fold headline. That raises a question about an old assay. The DDT comparison is based on fat solubility. In people given 50 mg, the parent drug’s plasma half-life was about one hour and its main breakdown product’s was about four days. If the claim is dangerous accumulation in human tissue, show the tissue exposure. https://t.co/KsvAQXFjsx · https://t.co/QiX8CuY07S · https://t.co/Z2o9fNgv5x
And the supposedly fictitious biology was measured in patients. Both doses raised miR-124 in blood and colon tissue versus placebo in Phase 3, following the same finding in Phase 2. The Phase 3 analysis included 673 paired sigmoid biopsies, alongside paired rectal biopsies and blood samples. Scorpion can question the old binding assay. It still has to deal with the separate structural work and the biological change measured in actual patients. https://t.co/5Hn6GighhG · https://t.co/tDramY7NsK · https://t.co/Bco1bipbNy · https://t.co/TpPQofWk6T
The cancer cases deserved a serious look in June. We did the math then, and the expanded 50 mg data landed right within our estimates of background cancer rates in ulcerative colitis patients. Scorpion has a set of lab hypotheses and a fraud headline and completely ignores the fact the drug has show ZERO EVIDENCE OF ANYTHING THEY CLAIM IN THOUSANDS OF HUMAN BEINGS AND THEREFORE IS MOST LIKELY COMPLETELY WRONG.
Abivax has two positive 50 mg induction trials, a positive randomized maintenance trial at both doses, and biopsies that show the colon getting healthier. If you want to overturn that record, bring CLINICAL EVIDENCE that can explain it.
$ABVX
so the big funds are so insanely cash strapped/illiquid that they are not touching this monumental dip? Buying opportunity?
Is the thesis so bad? Have we gotten it so wrong? 😂
$ABVX
Seriously, should management just sit-by like this hands in the air and in a french accent "Yehhh uhhh the market does what it should ehhh"
I think they should learn from the Adam Neumans, just a little. Can't just ride the 'asset' and wish for the best.
IN GTAVI, I heard you can hijack Lilly’s private jet with @DaveARicks onboard, and force the company’s board to buy $ABVX for $67 billion in exchange for his freedom.